Skip to main content
Erschienen in: Clinical & Experimental Metastasis 3/2012

01.03.2012 | Research Paper

The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma

verfasst von: Jane A. Cipollone, Marcia L. Graves, Martin Köbel, Steve E. Kalloger, Tak Poon, C. Blake Gilks, Kelly M. McNagny, Calvin D. Roskelley

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

High grade serous ovarian tumors often metastasize transperitoneally, a process that begins when small tumor nodules de-adhere and are released into the fluid of the abdominal cavity where they float freely to reach new sites on the peritoneal wall. Podocalyxin, a small anti-adhesive sialomucin, has been shown to contribute to non-adhesive membrane domain formation in some epithelia and is overexpressed in a variety of cancers. We therefore assessed podocalyxin expression on a previously characterized tissue microarray and found that 87% (169/194) of high grade serous epithelial ovarian carcinomas were positive for podocalyxin. In addition, cell surface localization of podocalyxin was associated with a significant decrease in disease-free survival in these tumors. When podocalyxin was force-expressed in serous ovarian carcinoma-derived OVCAR-3 cells it was targeted to the cell surface and it decreased the adhesion of these cells to mesothelial monolayers, fibronectin and immobilized β1 integrin-binding antibodies. This decrease in adhesion was associated with a modest decrease in cell surface β1 integrin. In monolayer culture, podocalyxin was targeted to the free, apical domains of OVCAR-3 cells and it appeared to decrease β1 integrin levels on the attached basolateral domains of the same cells. Furthermore, in 3-dimensional basement membrane gel culture, the cells formed small, cohesive nodules and podocalyxin localized to membrane domains at the cell–basement membrane interface. Therefore, podocalyxin’s ability to facilitate the formation of non-adhesive membrane domains may contribute to the formation of free-floating high grade serous tumor nodules during the initial steps of transperitoneal metastasis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society (2004) Cancer statistics. CA Cancer J Clin 54:8–29PubMedCrossRef Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society (2004) Cancer statistics. CA Cancer J Clin 54:8–29PubMedCrossRef
2.
Zurück zum Zitat Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT, Gynecologic Cancer Intergroup (2007) Clinical trials in gynecological cancer. Int J Gynecol Cancer 17(3):547–556PubMedCrossRef Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT, Gynecologic Cancer Intergroup (2007) Clinical trials in gynecological cancer. Int J Gynecol Cancer 17(3):547–556PubMedCrossRef
3.
Zurück zum Zitat Flam F, Einhorn N, Sjovall K (1988) Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 27:53–57PubMedCrossRef Flam F, Einhorn N, Sjovall K (1988) Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 27:53–57PubMedCrossRef
4.
Zurück zum Zitat Davidson B, Risberg B, Reich R, Berner A (2003) Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23:729–754PubMedCrossRef Davidson B, Risberg B, Reich R, Berner A (2003) Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23:729–754PubMedCrossRef
5.
Zurück zum Zitat Schopperle WM, Kershaw DB, DeWolf WC (2003) Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 300(2):285–290PubMedCrossRef Schopperle WM, Kershaw DB, DeWolf WC (2003) Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 300(2):285–290PubMedCrossRef
6.
Zurück zum Zitat Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED (2005) Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 124(1):134–142PubMedCrossRef Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED (2005) Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 124(1):134–142PubMedCrossRef
7.
Zurück zum Zitat Ney JT, Zhou H, Sipos B, Buttner R, Chen X, Kloppel G, Gutgemann I (2007) Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum Pathol 38(2):359–364PubMedCrossRef Ney JT, Zhou H, Sipos B, Buttner R, Chen X, Kloppel G, Gutgemann I (2007) Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum Pathol 38(2):359–364PubMedCrossRef
8.
Zurück zum Zitat Schopperle WM, DeWolf WC (2007) The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25(3):723–730PubMedCrossRef Schopperle WM, DeWolf WC (2007) The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25(3):723–730PubMedCrossRef
9.
Zurück zum Zitat Yasuoka H, Tsujimoto M, Hirokawa M, Tori M, Nakahara M, Miyauchi A, Kodama R, Sanke T, Nakamura Y (2008) Podocalyxin expression in undifferentiated thyroid carcinomas. J Clin Pathol 61(11):1228–1229PubMedCrossRef Yasuoka H, Tsujimoto M, Hirokawa M, Tori M, Nakahara M, Miyauchi A, Kodama R, Sanke T, Nakamura Y (2008) Podocalyxin expression in undifferentiated thyroid carcinomas. J Clin Pathol 61(11):1228–1229PubMedCrossRef
10.
Zurück zum Zitat Thomas SN, Schnaar RL, Konstantopoulos K (2009) Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol 296(3):C505–C513PubMedCrossRef Thomas SN, Schnaar RL, Konstantopoulos K (2009) Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol 296(3):C505–C513PubMedCrossRef
11.
Zurück zum Zitat Hsu YH, Lin WL, Hou YT, Pu YS, Shun CT, Chen CL, Wu YY, Chen JY, Chen TH, Jou TS (2010) Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 176(6):3050–3061PubMedCrossRef Hsu YH, Lin WL, Hou YT, Pu YS, Shun CT, Chen CL, Wu YY, Chen JY, Chen TH, Jou TS (2010) Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 176(6):3050–3061PubMedCrossRef
12.
Zurück zum Zitat Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS (2006) Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 15(5):735–741PubMedCrossRef Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS (2006) Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 15(5):735–741PubMedCrossRef
13.
Zurück zum Zitat Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD (2004) Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64(15):5068–5073PubMedCrossRef Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD (2004) Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64(15):5068–5073PubMedCrossRef
14.
Zurück zum Zitat Cheung H-H, Davis AJ, Lee T-L, Pang AL, Nagrani S, Rennert OM, Chan W-Y (2011) Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 30(31):3404–3415PubMedCrossRef Cheung H-H, Davis AJ, Lee T-L, Pang AL, Nagrani S, Rennert OM, Chan W-Y (2011) Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 30(31):3404–3415PubMedCrossRef
15.
Zurück zum Zitat Kerjaschki D, Sharkey DJ, Farquhar MG (1984) Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 98:1591–1596PubMedCrossRef Kerjaschki D, Sharkey DJ, Farquhar MG (1984) Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 98:1591–1596PubMedCrossRef
16.
Zurück zum Zitat Dekan G, Miettinen A, Schnabel E, Farquhar MG (1990) Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. Am J Pathol 137(4):913–927PubMed Dekan G, Miettinen A, Schnabel E, Farquhar MG (1990) Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. Am J Pathol 137(4):913–927PubMed
17.
Zurück zum Zitat Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM (2001) Anuria, omphalocele, and perinatal lethality in mice lacking the CD-34-related protein podocalyxin. J Exp Med 194:13–27PubMedCrossRef Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM (2001) Anuria, omphalocele, and perinatal lethality in mice lacking the CD-34-related protein podocalyxin. J Exp Med 194:13–27PubMedCrossRef
18.
Zurück zum Zitat Miettinen A, Solin ML, Reivinen J, Juvonen E, Vaisanen R, Holthofer H (1999) Podocalyxin in rat platelets and megakaryocytes. Am J Pathol 154(3):813–822PubMedCrossRef Miettinen A, Solin ML, Reivinen J, Juvonen E, Vaisanen R, Holthofer H (1999) Podocalyxin in rat platelets and megakaryocytes. Am J Pathol 154(3):813–822PubMedCrossRef
19.
Zurück zum Zitat Vitureira N, McNagny K, Soriano E, Burgaya F (2005) Pattern of expression of the podocalyxin gene in the mouse brain during development. Gene Expr Patterns 5(3):349–354PubMedCrossRef Vitureira N, McNagny K, Soriano E, Burgaya F (2005) Pattern of expression of the podocalyxin gene in the mouse brain during development. Gene Expr Patterns 5(3):349–354PubMedCrossRef
20.
Zurück zum Zitat Meder D, Shevchenko A, Simons K, Füllekrug J (2005) Gp135/podocalyxin and NHERF-2 participate in the formation of a preapical domain during polarization of MDCK cells. J Cell Biol 168(2):303–313PubMedCrossRef Meder D, Shevchenko A, Simons K, Füllekrug J (2005) Gp135/podocalyxin and NHERF-2 participate in the formation of a preapical domain during polarization of MDCK cells. J Cell Biol 168(2):303–313PubMedCrossRef
21.
Zurück zum Zitat Nielsen JS, McCoy M, Chelliah S, Vogl AW, Roskelley CD, McNagny KM (2007) The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS ONE 2:e237PubMedCrossRef Nielsen JS, McCoy M, Chelliah S, Vogl AW, Roskelley CD, McNagny KM (2007) The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS ONE 2:e237PubMedCrossRef
22.
Zurück zum Zitat Strilic B, Kucera T, Eglinger J, Hughes MR, McNagny KM, Tsukita S, Dejana E, Ferrara Lammert E (2009) The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 17(4):505–515PubMedCrossRef Strilic B, Kucera T, Eglinger J, Hughes MR, McNagny KM, Tsukita S, Dejana E, Ferrara Lammert E (2009) The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 17(4):505–515PubMedCrossRef
23.
Zurück zum Zitat Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288PubMedCrossRef Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288PubMedCrossRef
24.
Zurück zum Zitat Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443PubMedCrossRef Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443PubMedCrossRef
25.
Zurück zum Zitat Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27(1):1–9PubMedCrossRef Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27(1):1–9PubMedCrossRef
26.
Zurück zum Zitat Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC (1997) Molecular cloning and characterization of human podocalyxin-like protein. J Biol Chem 272(25):15708–15714PubMedCrossRef Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC (1997) Molecular cloning and characterization of human podocalyxin-like protein. J Biol Chem 272(25):15708–15714PubMedCrossRef
27.
Zurück zum Zitat Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39(8):1239–1251PubMedCrossRef Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39(8):1239–1251PubMedCrossRef
28.
Zurück zum Zitat Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):e232PubMedCrossRef Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):e232PubMedCrossRef
29.
Zurück zum Zitat Graves ML, Zhou L, MacDonald G, Mueller CR, Roskelley CD (2007) Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells. FEBS Lett 581(9):1825–1833PubMedCrossRef Graves ML, Zhou L, MacDonald G, Mueller CR, Roskelley CD (2007) Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells. FEBS Lett 581(9):1825–1833PubMedCrossRef
30.
Zurück zum Zitat Connell ND, Rheinwald JG (1983) Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 34(1):245–253PubMedCrossRef Connell ND, Rheinwald JG (1983) Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 34(1):245–253PubMedCrossRef
31.
Zurück zum Zitat Pinkas J, Leder P (2002) Mek1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of epithelial to mesenchymal transition. Cancer Res 62:4781–4790PubMed Pinkas J, Leder P (2002) Mek1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of epithelial to mesenchymal transition. Cancer Res 62:4781–4790PubMed
32.
Zurück zum Zitat Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43(11):5379–5389PubMed Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43(11):5379–5389PubMed
33.
Zurück zum Zitat Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J (1995) Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol 58:216–225PubMedCrossRef Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J (1995) Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol 58:216–225PubMedCrossRef
34.
Zurück zum Zitat Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL (2003) Cyclic AMP induces integrin-mediated adhesion through Epac and Rap1 upon stimulation of the β2-adrenergic receptor. J Cell Biol 160:487–493PubMedCrossRef Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL (2003) Cyclic AMP induces integrin-mediated adhesion through Epac and Rap1 upon stimulation of the β2-adrenergic receptor. J Cell Biol 160:487–493PubMedCrossRef
35.
Zurück zum Zitat Takeda T, Go WY, Orlando RA, Farquhar MG (2000) Expression of podocalyxin inhibits cell–cell adhesion and modifies junctional properties in madin-Darby Canine Kidney Cells. Mol Biol Cell 11:3219–3232PubMed Takeda T, Go WY, Orlando RA, Farquhar MG (2000) Expression of podocalyxin inhibits cell–cell adhesion and modifies junctional properties in madin-Darby Canine Kidney Cells. Mol Biol Cell 11:3219–3232PubMed
36.
Zurück zum Zitat Abdullah KM, Udoh EA, Shewen PE, Mellors A (1992) A neutral glycoprotease of Pasteurella haemolytica A1 specifically cleaves O-sialoglycoproteins. Infect Immun 60:56–62PubMed Abdullah KM, Udoh EA, Shewen PE, Mellors A (1992) A neutral glycoprotease of Pasteurella haemolytica A1 specifically cleaves O-sialoglycoproteins. Infect Immun 60:56–62PubMed
37.
Zurück zum Zitat Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93(1):170–181PubMedCrossRef Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93(1):170–181PubMedCrossRef
38.
Zurück zum Zitat Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19(1):3–9PubMedCrossRef Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19(1):3–9PubMedCrossRef
39.
Zurück zum Zitat Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25(25):3985–3990PubMedCrossRef Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25(25):3985–3990PubMedCrossRef
40.
Zurück zum Zitat Fountain J, Trimble E, Birrer MJ (2006) Summary and discussion of session recommendations. Gynecol Oncol 103(2, Suppl 1):S23–S25PubMedCrossRef Fountain J, Trimble E, Birrer MJ (2006) Summary and discussion of session recommendations. Gynecol Oncol 103(2, Suppl 1):S23–S25PubMedCrossRef
41.
Zurück zum Zitat Francis SS, Sfakianos J, Lo B, Mellman I (2011) A hierarchy of signals regulates entry of membrane proteins into the ciliary membrane domain in epithelial cells. J Cell Biol 193:219–233PubMedCrossRef Francis SS, Sfakianos J, Lo B, Mellman I (2011) A hierarchy of signals regulates entry of membrane proteins into the ciliary membrane domain in epithelial cells. J Cell Biol 193:219–233PubMedCrossRef
42.
Zurück zum Zitat Li Y, Li J, Straight SW, Kershaw DB (2002) PDZ domain-mediated interaction of rabbit podocalyxin and Na(+)/H(+) exchange regulatory factor-2. Am J Physiol Renal Physiol 282:F1129–F1139PubMed Li Y, Li J, Straight SW, Kershaw DB (2002) PDZ domain-mediated interaction of rabbit podocalyxin and Na(+)/H(+) exchange regulatory factor-2. Am J Physiol Renal Physiol 282:F1129–F1139PubMed
43.
Zurück zum Zitat Tan PC, Furness SG, Merkens H, Lin S, McCoy ML, Roskelley CD, Kast J, McNagny KM (2006) Na+/H+ exchanger regulatory factor-1 is a hematopoietic ligand for a subset of the CD34 family of stem cell surface proteins. Stem Cells 24:1150–1161PubMedCrossRef Tan PC, Furness SG, Merkens H, Lin S, McCoy ML, Roskelley CD, Kast J, McNagny KM (2006) Na+/H+ exchanger regulatory factor-1 is a hematopoietic ligand for a subset of the CD34 family of stem cell surface proteins. Stem Cells 24:1150–1161PubMedCrossRef
44.
Zurück zum Zitat Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, Furthmayr H, Farquhar MG (2001) The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 12:1589–1598PubMed Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, Furthmayr H, Farquhar MG (2001) The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 12:1589–1598PubMed
45.
Zurück zum Zitat Takeda T, McQuistran T, Orlando RA, Farquhar MG (2001) Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 108:289–301PubMed Takeda T, McQuistran T, Orlando RA, Farquhar MG (2001) Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 108:289–301PubMed
46.
Zurück zum Zitat Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G (2007) Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67(13):6183–6191PubMedCrossRef Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G (2007) Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67(13):6183–6191PubMedCrossRef
47.
Zurück zum Zitat Meng X, Ezzati P, Wilkins JA (2011) Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS ONE 6(4):e18715PubMedCrossRef Meng X, Ezzati P, Wilkins JA (2011) Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS ONE 6(4):e18715PubMedCrossRef
48.
Zurück zum Zitat Kobel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S (2006) Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 25(2):121–130PubMedCrossRef Kobel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S (2006) Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 25(2):121–130PubMedCrossRef
49.
Zurück zum Zitat Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB (2010) Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 29(2):99–107PubMedCrossRef Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB (2010) Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 29(2):99–107PubMedCrossRef
50.
Zurück zum Zitat Klausen C, Leung PC, Auersperg N (2009) Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of β1 integrin. Mol Cancer Res 7(9):1425–1437PubMedCrossRef Klausen C, Leung PC, Auersperg N (2009) Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of β1 integrin. Mol Cancer Res 7(9):1425–1437PubMedCrossRef
Metadaten
Titel
The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma
verfasst von
Jane A. Cipollone
Marcia L. Graves
Martin Köbel
Steve E. Kalloger
Tak Poon
C. Blake Gilks
Kelly M. McNagny
Calvin D. Roskelley
Publikationsdatum
01.03.2012
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 3/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9446-0

Weitere Artikel der Ausgabe 3/2012

Clinical & Experimental Metastasis 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.